Daiichi Sankyo Company, Limited · TSE:4568
Daiichi Sankyo — FY2016 Q3 Earnings Presentation
36 slides from Daiichi Sankyo's earnings presentation, Jan 31, 2017
Slide 1: Top Management Presentation: Financial Results for FY2016 Q3
Top Management Presentation Financial Results for FY2016 Q3 (April 1 – December 31, 2016) DAIICHI SANKYO CO., LTD George Nakayama President and CEO January 31, 2017
Slide 2: Forward-Looking Statements
Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward looking statements were determined by Daiichi Sa
Slide 3: Agenda
Agenda FY2016 Q3 Financial Results FY2016 Revised Consolidated Forecast Management Updates Grow Edoxaban Maximize Sales Potential of Injectafer R&D Updates Strategic Partnership for Cellular Therapy Pipeline with Kite Pharma ADC Franchise Enhancement 2
Slide 4: FY2016 Q3 Financial Results
FY2016 Q3 Financial Results 3
Slide 5: Overview of FY2016 Q3 Results
Overview of FY2016 Q3 Results (JPY Bn) FY2015 Q3 YTD FY2016 Q3 YTD YoY Results Results -3.2% Revenue 758.6 734.4 -24.2 Cost of Sales 237.7 241.7 +4.0 SG&A Expenses 232.3 220.5 -11.8 R&D Expenses 138.1 143.5 +5.4 -14.4% Operating Profit 150.4 128.7 -21.7 Profit before Tax 145.4 132.4 -13.0 -20.4% Pro
Slide 6: Revenue
Revenue Decreased by 24.2 Bn JPY (Increased by 16.6 Bn JPY excl. forex impact) (JPY Bn) FY2015 Results 758.6 Japan Positive : Lixiana +8.3 Tenelia +7.8 Japan Nexium +5.5 Inavir +5.4 (incl. Vaccines, OTC) 24.5 Efient +4.6 Pralia +4.3 Memary +3.7 Daiichi Sankyo, Inc. (US) 13.4 Negative : Loxonin -8.9
Slide 7: Operating Profit
Operating Profit Decreased by 21.7 Bn JPY (Increased by 1.8 Bn JPY excl. forex impact and special items) (JPY Bn) FY2015 Results 150.4 Revenue -24.2 incl. forex impact -40.8 Revenue 24.2 Cost of Sales +10.6 Increased in revenue excl. forex impact Cost of Sales 10.6 Impact of price revision in Japan
Slide 8: Special Items
Special Items (JPY Bn) FY2015 Q3 YTD Results FY2016 Q3 YTD Results YoY Gain on sales of subsidiary -2.4 Cost of Sales ‐ +3.5 Gain on sales of fixed assets -1.1 SG&A Restructuring costs in US 6.1 Restructuring costs 10.6 Expenses +12.7 Gain on sales of fixed assets -8.2 R&D Expenses Restructuring cos
Slide 9: Profit Attributable to Owners of the Company
Profit Attributable to Owners of the Company Decreased by 22.5 Bn JPY (JPY Bn) FY2015 Results 110.7 Operating Profit 21.7 Financial Income / Expenses -8.4 Financial Income Improvement of forex gains/ losses / Expenses 8.4 FY2015: Expenses relating to the sales of Sun Pharma shares etc. Income Taxes
Slide 10: Major Business Units
Major Business Units (JPY Bn) FY2015 FY2016 vs. Forecast* Q3 YTD Q3 YTD YoY (%) Results Results Japan 377.5 390.2 +12.8 77.3% Daiichi Sankyo Healthcare 39.9 51.9 +12.0 78.6% Daiichi Sankyo Inc. 145.5 115.8 -29.7 80.4% Olmesartan 88.4 60.9 -27.5 84.6% Welchol 37.7 32.2 -5.5 78.5% Effient 16.4 16.5 +0
Slide 11: Major Products in Japan
Major Products in Japan (JPY Bn) FY2015 FY2016 vs. Forecast* Q3 YTD Q3 YTD YoY (%) Results Results Nexium ulcer treatment 62.0 67.4 +5.5 81.2% Olmetec antihypertensive agent 60.5 54.1 -6.4 78.4% Alzheimer’s disease Memary treatment 32.7 36.3 +3.7 74.2% Loxonin anti-inflammatory analgesic 38.2 29.3 -
Slide 12: FY2016 Revised Consolidated Forecast
FY2016 Revised Consolidated Forecast 11
Slide 13: FY2016 Revised Consolidated Forecast
FY2016 Revised Consolidated Forecast (JPY Bn) FY2016 FY2016 Major factors vs. Forecast Forecast Forecast -Forex impact +13.0 (as of Oct.) (as of Oct.) (as of Jan.) -Japan +6.0 -Overseas +9.0 Revenue 920.0 950.0 +30.0 Major factors Cost of Sales 307.0 318.0 +11.0 -Forex impact +3.0 -Increase by incre
Slide 14: Grow Edoxaban
Dalichi-Sankyo Grow Edoxaban 13
Slide 15: Edoxaban: Japan
Edoxaban: Japan The DOAC market in Japan is expanding steadily. The sales market share of Lixiana has reached 14.3% (CY base). (JPY Bn) 165.5 150 23.7 14.3% 129.0 120 12.8 9.9% 88.9 90 1.4 1.6% 60 Lixiana 30 0 CY2014 CY2015 CY2016 Copyright © 2017 QuintilesIMS Calculated based on JPM Sales Data 2014
Slide 16: Edoxaban: Japan market share in new patients
10 15 20 25 30 35 0 5 (%) Sep-14 Oct-14 Nov-14 Dec-14 Source :Medi-trend Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Edoxaban: Japan Aug-15 Sep-15 Oct-15 in new patients for AF+VTE. Nov-15 Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 As of Nov. 2016, Lixia
Slide 17: Edoxaban: Germany and South Korea
Edoxaban: Germany and South Korea Steady uptake of sales share after launch (%) (%) Germany South Korea 6 5.5% 12 10.8% 5 10 4 8 3 6 2 4 1 2 0 0 Feb-16 Jan-16 Mar-16 Jun-16 Jan-16 Feb-16 Mar-16 Jun-16 Jul-16 Jul-16 Oct-16 May-16 Aug-16 Sep-16 Oct-16 Nov-15 Dec-15 Apr-16 Nov-16 May-16 Aug-16 Sep-16 A
Slide 18: Maximize Sales Potential of Injectafer
Maximize Sales Potential of Injectafer 17
Slide 19: Untapped Potential of Injectafer
Untapped Potential of Injectafer Injectafer* has grown steadily in the US IV Iron market. However there is still potential for further growth. US IV Iron Market (includes dialysis) 800 760.8 700 655.1 28.9% 600 577.5 19.2% 8.8% 500 15.9% 17.3% 16.1% Injectafer $M 400 7.3% 6.3% 5.0% 8.5% 7.6% 6.3% 30
Slide 20: Former Design
Former Design In IDA* treatment, market beyond Oncologist and Hem/Onc. has not been tapped since LPI focused its limited resources on the area of Oncologist and Hem/Onc. Chronic Women’s IBD/ ND-CKD Heart Oncology Health GI Failure Patients’ Visit to Hospitals / Clinics / Physician Offices OBGYN Card
Slide 21: New Design as of Jan. 2017
New Design as of Jan. 2017 LPI sales team for Injectafer has become DSI employees. DSI/LPI formed a united sales team for Injectafer to accelerate growth. Chronic Women’s IBD/ ND-CKD Oncology Heart Health GI Failure Patients’ Visit to Hospitals / Clinics / Physician Offices OBGYN Cardiologist Gastro
Slide 22: Additional Effect on DS Group's US Business by United Sales Team
Additional Effect on DS Group’s US Business by United Sales Team for Injectafer United sales team for Injectafer To accelerate growth beyond oncologist and hem/onc Leverage DSI’s existing sales & marketing infrastructure for Injectafer Establish a foundation for DSI’s oncology business leveraging
Slide 23: Strategic Partnership for Cellular Therapy Pipeline with Kite Pharma
Strategic Partnership for Cellular Therapy Pipeline with Kite Pharma 22
Slide 24: Strategic Partnership for Cellular Therapy Pipeline with Kite Pharma
Strategic Partnership for Cellular Therapy Pipeline with Kite Pharma Kite Pharma, Inc. (Kite) Located in California, US, Established in 2009, NASDAQ IPO in 2014 One of the leading development companies for engineered T-cell* therapy in oncology * Chimera Antigen Receptor T-cell: CAR-T T-cell R
Slide 25: Chimera Antigen Receptor T-cell: CAR-T
Chimera Antigen Receptor T-cell: CAR-T From Kite IR material 24
Slide 26: Production timeline of engineered T-cell
Production timeline of engineered T-cell Employing refined and optimized process, therapeutic T-cell is available within 16-18 days with high probability of production success (97%) * Medical center Cell engineering facility Medical center Selection of patients Quality Preparation Collection of Tran
Slide 27: KTE-C19
KTE-C19 Development Status Several clinical studies including non-Hodgkin's lymphoma are on-going US: Breakthrough Therapy Designation(DLBCL1/TFL2/PMBCL3) Rolling BLA submission for refractory aggressive non-Hodgkin lymophoma was initiated in Dec 2016 and will be completed in CY2017 Q1 EU:PRIM
Slide 28: KTE-C19: ZUMA-1 Interim Analysis
KTE-C19 ZUMA-1 Phase 2 Interim Analysis(ASH 2016) Chemorefractory patients with DLBCL, TFL, PMBCL 76 % of patients with DLBCL achieved objective response (p < 0.0001) and 47 % complete remissions (CR) at pre-specified interim analysis Adverse events in patients with a minimum one month follow
Slide 29: ADC franchise enhancement
ADC franchise enhancement 28
Slide 30: ADC franchise enhancement: U3-1402 HER3-ADC
ADC franchise enhancement: U3-1402 HER3-ADC Linker & Payload: same as DS-8201 Triggered by binding of Antibody:Patritumab patritumab, 60-80% of HER3 are internalized U3-1402 HER3-ADC Desirable characterization for ADC 29
Slide 31: U3-1402 HER3-ADC: non-clinical xenograft data
ADC franchise enhancement: U3-1402 HER3-ADC Patient-derived HER3-positive (HER2- 1. HER3 overexpression is negative) Xenograft models reported in breast cancer (BC) and correlated with poor prognosis* - HR+ BC model - - TNBC model - Unmet Medical Needs for Estimated tumor volume, (mm^3) 2000 BC wi
Slide 32: U3-1402 HER3-ADC: Phase 1/2 study
ADC franchise enhancement: U3-1402 HER3-ADC Initiated Phase 1/2 study in Japan Research participants HER3-positive advanced/unresectable metastatic breast cancer, treated with standard treatment, or no standard treatment is available Study design(estimated enrollment: 80) Dose escalation p
Slide 33: Major R&D milestone events
Major R&D milestone events Project Indication/Study Event Target Pain/Opioid-induced nausea and vomiting PDUFA date CL-108 (US) Approval Jan. 31, 2017 Denosumab Rheumatoid arthritis (JP) Approval FY2017 CHS-0214 Rheumatoid arthritis (JP) NDA FY2016 (etanercept BS) METIV・HCC Hepatocellular carcinoma
Slide 34: Reference
Dalichi-Sankyo 33
Slide 35: Major R&D Pipeline
Major R&D Pipeline As of January 2017 Therapeutic area Phase 1 Phase 2 Phase 3 Application DS-3032 (US/JP) DS-8895 (JP) Patritumab (EU) Tivantinib (US/EU) (MDM2 inhibitor) (Anti-EPHA2 antibody) (U3-1287 / Anti-HER3 antibody) (ARQ 197 / HCC / MET inhibitor) PLX7486 (US) DS-8273 (US) Deno
Slide 36: Contact address regarding this material
Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Email: [email protected]
Daiichi Sankyo Company — FY2016 Q3 Earnings Presentation on 6ix